204 related articles for article (PubMed ID: 8339259)
1. Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.
Lelievre E; Guillaudeux J; Cardona H; Bourguignat A; Lokiec F; Solere P; Lucas C; Sauveur C
Cancer Res; 1993 Aug; 53(15):3536-40. PubMed ID: 8339259
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics of vinblastine and the investigational Vinca alkaloid N-(deacetyl-O-4-vinblastoyl-23)-L-ethyl isoleucinate in mice as determined by high-performance liquid chromatography.
van Tellingen O; Beijnen JH; Nooijen WJ; Bult A
Cancer Res; 1993 May; 53(9):2061-5. PubMed ID: 8481908
[TBL] [Abstract][Full Text] [Related]
3. The clinical pharmacokinetics of vinorelbine (Navelbine).
Wargin WA; Lucas VS
Semin Oncol; 1994 Oct; 21(5 Suppl 10):21-7. PubMed ID: 7973765
[TBL] [Abstract][Full Text] [Related]
4. [Analytical limits in clinical pharmacokinetics: example of vinca-alkaloids].
Solere P; Lucas C
Bull Cancer; 1991; 78(9):775-87. PubMed ID: 1751829
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolism of vinca alkaloids.
Rahmani R; Zhou XJ
Cancer Surv; 1993; 17():269-81. PubMed ID: 8137344
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies to antitumor Vinca alkaloids: thermodynamics and kinetics.
Pontarotti PA; Rahmani R; Martin M; Barbet J
Mol Immunol; 1985 Mar; 22(3):277-84. PubMed ID: 4000131
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.
Atassi G; Berlion M; el Oche Y; Bizzari JP
Anticancer Res; 1991; 11(2):975-80. PubMed ID: 2064354
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological properties of a new alpha-aminophosphonic acid derivative of vinblastine.
Pierré A; Lavielle G; Hautefaye P; Seurre G; Leonce S; Saint-Dizier D; Boutin JA; Cudennec CA
Anticancer Res; 1990; 10(1):139-44. PubMed ID: 2334119
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine).
Rahmani R; Martin M; Barbet J; Cano JP
Cancer Res; 1984 Dec; 44(12 Pt 1):5609-13. PubMed ID: 6498821
[TBL] [Abstract][Full Text] [Related]
10. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells.
Jean-Decoster C; Brichese L; Barret JM; Tollon Y; Kruczynski A; Hill BT; Wright M
Anticancer Drugs; 1999 Jul; 10(6):537-43. PubMed ID: 10885901
[TBL] [Abstract][Full Text] [Related]
11. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.
Lobert S; Vulevic B; Correia JJ
Biochemistry; 1996 May; 35(21):6806-14. PubMed ID: 8639632
[TBL] [Abstract][Full Text] [Related]
12. Positive interaction of bisbenzylisoquinoline alkaloid, cepharanthin, with vinca alkaloid agents against human tumors.
Ono M; Tanaka N
In Vivo; 1997; 11(3):233-41. PubMed ID: 9239517
[TBL] [Abstract][Full Text] [Related]
13. Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.
Spearman ME; Goodwin RM; Apelgren LD; Bumol TF
J Pharmacol Exp Ther; 1987 May; 241(2):695-703. PubMed ID: 3494841
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
15. Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse.
Dorr RT; Alberts DS
J Natl Cancer Inst; 1985 Jan; 74(1):113-20. PubMed ID: 3855472
[TBL] [Abstract][Full Text] [Related]
16. Disposition of the monoclonal antibody-vinca alkaloid conjugate, KS1/4-DAVLB (LY256787), in Fischer 344 rats and rhesus monkeys.
Spearman ME; Goodwin RM; Kau D
Drug Metab Dispos; 1987; 15(5):640-7. PubMed ID: 2891480
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics of the antitumor drug navelbine (5'-noranhydrovinblastine).
Rahmani R; Bruno R; Iliadis A; Favre R; Just S; Barbet J; Cano JP
Cancer Res; 1987 Nov; 47(21):5796-9. PubMed ID: 3664483
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of vindesine and vincristine in humans.
Owellen RJ; Root MA; Hains FO
Cancer Res; 1977 Aug; 37(8 Pt 1):2603-7. PubMed ID: 872088
[TBL] [Abstract][Full Text] [Related]
19. Oral versus intravenous vinorelbine: clinical safety profile.
Gebbia V; Puozzo C
Expert Opin Drug Saf; 2005 Sep; 4(5):915-28. PubMed ID: 16111453
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
